QSI vs. EYPT, TRNS, ALNT, AEHR, CTKB, LAB, SENS, FEIM, QTRX, and MASS
Should you be buying Quantum-Si stock or one of its competitors? The main competitors of Quantum-Si include Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Allient (ALNT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Quantum-Si vs. Its Competitors
Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Quantum-Si (NASDAQ:QSI) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.
Quantum-Si has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.
Eyepoint Pharmaceuticals presently has a consensus target price of $26.86, suggesting a potential upside of 131.53%. Quantum-Si has a consensus target price of $3.48, suggesting a potential upside of 202.17%. Given Quantum-Si's higher possible upside, analysts clearly believe Quantum-Si is more favorable than Eyepoint Pharmaceuticals.
Eyepoint Pharmaceuticals has a net margin of -337.93% compared to Quantum-Si's net margin of -3,120.14%. Quantum-Si's return on equity of -44.57% beat Eyepoint Pharmaceuticals' return on equity.
Eyepoint Pharmaceuticals has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Quantum-Si has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500.
99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 30.0% of Quantum-Si shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Eyepoint Pharmaceuticals had 6 more articles in the media than Quantum-Si. MarketBeat recorded 7 mentions for Eyepoint Pharmaceuticals and 1 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 1.87 beat Eyepoint Pharmaceuticals' score of 1.07 indicating that Quantum-Si is being referred to more favorably in the news media.
Summary
Quantum-Si beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Quantum-Si News Delivered to You Automatically
Sign up to receive the latest news and ratings for QSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quantum-Si Competitors List
Related Companies and Tools
This page (NASDAQ:QSI) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access